Related Experiment Video
Updated: Nov 25, 2025

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations
Published on: August 4, 2016
annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions
Krutika S Gaonkar1,2,3, Federico Marini4,5, Komal S Rathi1,2,3
1Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Background:
Gene fusion events are significant sources of somatic variation across adult and pediatric cancers and are some of the most clinically-effective therapeutic targets, yet low consensus of RNA-Seq fusion prediction algorithms makes therapeutic prioritization difficult. In addition, events such as polymerase read-throughs, mis-mapping due to gene homology, and fusions occurring in healthy normal tissue require informed filtering, making it difficult for researchers and clinicians to rapidly discern gene fusions that might be true underlying oncogenic drivers of a tumor and in some cases, appropriate targets for therapy.
Results:
We developed annoFuse, an R package, and shinyFuse, a companion web application, to annotate, prioritize, and explore biologically-relevant expressed gene fusions, downstream of fusion calling. We validated annoFuse using a random cohort of TCGA RNA-Seq samples (N = 160) and achieved a 96% sensitivity for retention of high-confidence fusions (N = 603). annoFuse uses FusionAnnotator annotations to filter non-oncogenic and/or artifactual fusions. Then, fusions are prioritized if previously reported in TCGA and/or fusions containing gene partners that are known oncogenes, tumor suppressor genes, COSMIC genes, and/or transcription factors. We applied annoFuse to fusion calls from pediatric brain tumor RNA-Seq samples (N = 1028) provided as part of the Open Pediatric Brain Tumor Atlas (OpenPBTA) Project to determine recurrent fusions and recurrently-fused genes within different brain tumor histologies. annoFuse annotates protein domains using the PFAM database, assesses reciprocality, and annotates gene partners for kinase domain retention. As a standard function, reportFuse enables generation of a reproducible R Markdown report to summarize filtered fusions, visualize breakpoints and protein domains by transcript, and plot recurrent fusions within cohorts. Finally, we created shinyFuse for algorithm-agnostic interactive exploration and plotting of gene fusions.
Conclusions:
annoFuse provides standardized filtering and annotation for gene fusion calls from STAR-Fusion and Arriba by merging, filtering, and prioritizing putative oncogenic fusions across large cancer datasets, as demonstrated here with data from the OpenPBTA project. We are expanding the package to be widely-applicable to other fusion algorithms and expect annoFuse to provide researchers a method for rapidly evaluating, prioritizing, and translating fusion findings in patient tumors.
Insights
Researchers developed annoFuse, an R package, and shinyFuse, a web application, to effectively filter and prioritize gene fusions in cancer. These tools aid in identifying potential oncogenic drivers and therapeutic targets from RNA-Seq data.
Area of Science:
- Genomics
- Bioinformatics
- Cancer Research
Background:
- Gene fusions are key drivers in various cancers, presenting therapeutic opportunities.
- Challenges exist in accurately identifying and prioritizing oncogenic gene fusions due to algorithm variability and artifacts.
- Distinguishing true oncogenic fusions from artifacts is crucial for effective cancer therapy.
Purpose of the Study:
- To develop annoFuse, an R package, and shinyFuse, a web application, for annotating, prioritizing, and exploring gene fusions.
- To provide a standardized method for filtering and prioritizing putative oncogenic fusions from RNA-Seq data.
- To facilitate the rapid evaluation and translation of gene fusion findings in patient tumors.
Main Methods:
- Developed annoFuse (R package) and shinyFuse (web application) for gene fusion analysis.
- Validated annoFuse on TCGA RNA-Seq samples, achieving 96% sensitivity for high-confidence fusions.
- Applied annoFuse to pediatric brain tumor RNA-Seq data to identify recurrent fusions and fused genes.
Main Results:
- annoFuse demonstrated high sensitivity (96%) in retaining high-confidence gene fusions.
- The package filters non-oncogenic and artifactual fusions using FusionAnnotator annotations.
- Prioritization criteria include TCGA reports, known oncogenes, tumor suppressors, COSMIC genes, and transcription factors.
- Analysis of pediatric brain tumor data identified recurrent fusions and fused genes within specific histologies.
- Tools annotate protein domains, assess reciprocality, and identify kinase domain retention.
Conclusions:
- annoFuse offers standardized filtering and annotation for gene fusion calls from STAR-Fusion and Arriba.
- The package effectively merges, filters, and prioritizes oncogenic fusions across large cancer datasets.
- Future expansion aims for broader applicability to other fusion-calling algorithms.
- annoFuse is expected to accelerate the evaluation and translation of fusion findings for clinical application.
More Related Videos
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
09:58Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
Related Concept Videos
RNA-seq
Before the discovery of RNA-seq, microarray-based methods and Sanger sequencing were used for transcriptome analysis. However, while...
Tagging and Fusion Proteins